Cure Recession Blues With These Red-Hot Healthcare Stocks

Viemed Healthcare Inc. (TSX:VMD) and one other medical stock could reward Canadian investors with upside, even despite a recession.

| More on:
Pills spilling out of a prescription pot

Image source: Getty Images.

Healthcare is often seen as recession-proof, but the following two stocks also have the potential to make a bold investor rich. Having sifted through the available options, this duo of tickers represents a long-range value option and a high-growth option that could offer some quick upside. Let’s take a look at the stories behind two of the most popular medical stocks on the TSX and see whether either of them is a buy.

Viemed Healthcare

Covering two key areas of niche medical treatment, Viemed (TSX:VMD) produces solutions for neuromuscular patients as well as for sufferers with respiratory disease, sleep apnea, and oxygen-related conditions. This growth stock leaped 85% so far this year and more than doubled last year. While this means that the stock could obviously be cheaper — and its fundamentals indicate the same — the upside potential makes the stock a buy at almost any price.

Capital gains investors have a clear opportunity to make some serious dough by trading this stock. Go right back to January 2018, and you’ll see that the share price hasn’t stopped climbing since then. Though a spike caused a subsequent drop-off in mid-November, the trend has been otherwise steeply positive — particularly so this summer. A dip in the share price presents a rare value opportunity, making any subsequent gains even greater.

Immunovaccine

Having doubled in the past couple of years, IMV (TSX:IMV)(NASDAQ:IMV) is no stranger to growth, though its share price has been somewhat beaten up of late. Still, if good value for money suits your investment style, IMV could fit nicely into the healthcare section of a long-range capital gains-based portfolio of stocks. With a focus on biopharmaceutical treatments for cancer as well as other immunotherapies, this stock could soar on good news from the labs.

Whether the bottom has been reached just yet isn’t clear, though there’s a wide margin for profit from this stock that recently hit a year-long low. While the share price has managed to climb back off its 52-week low, at $3.74 a pop, it’s still a long way off even its low target price of $7.95. And while it seems an exciting prospect for hopeful shareholders, its high target price of $15.29 seems almost unfeasibly steep from this vantage point.

Still, considering that IMV saw $8.49 in the last 12 months, there’s every reason — especially given favourable lab results — that an investor could double their money here. One of the biggest reasons to get invested is IMV’s market share. Niche medical treatments are few and far between in the upper echelons of the TSX, and IMV is one of the better ones. In short, if you’re looking for a downturn-hardy investment with upside potential, look no further.

The bottom line

Niche markets cornered by thriving companies whose stock can seriously multiply an investor’s wealth are like gold mines for portfolios centred on growth. With the call for a recession gaining mainstream traction and any number of signs of a downturn amassing on the horizon, healthcare stocks should form part of a TSX investor’s defensive strategy, with the two tickers listed above being suitable examples of what to buy to stay safe while making a profit.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Victoria Hetherington has no position in any of the stocks mentioned. The Motley Fool owns shares of Viemed Healthcare Inc. Viemed Healthcare Inc. is a recommendation of Hidden Gems Canada.

More on Dividend Stocks

analyze data
Dividend Stocks

Got $250? Here Are 3 Smart Stocks to Buy Now

Are you looking for some smart stocks to buy? Here are three options that offer growth and income that you…

Read more »

Profit dial turned up to maximum
Dividend Stocks

2 TSX Stocks to Buy With Dividends Yielding More Than 3%

These two TSX stocks offer ultra-high dividends and, more importantly, stability towards a solid future of passive-income payments.

Read more »

Female hand holding piggy bank. Save money and financial investment
Dividend Stocks

Passive Income: 3 Top TSX Stocks That Pay Dividends Monthly

Given their high yields, attractive valuations, and stable cash flows, these three TSX stocks are excellent buys for income-seeking investors.

Read more »

Man making notes on graphs and charts
Dividend Stocks

Put Your Cash to Work: 3 Cheap TSX Stocks (With Dividend Yields of +5%) to Buy Now

Make your money work for you. Earn over 5% dividend yields with these under-$20 stocks.

Read more »

edit Woman calculating figures next to a laptop
Dividend Stocks

2 Oversold TSX Stocks for TFSA and RRSP Investors to Buy Now

These top TSX dividend stocks look oversold.

Read more »

Pixelated acronym REIT made from cubes, mosaic pattern
Dividend Stocks

2 Top High-Yielding REITs to Beat Inflation

Real estate investors can beat the 7% inflation by investing in these two high-yielding REITs.

Read more »

Increasing yield
Dividend Stocks

Passive-Income Alert: 2 Top TSX Stocks to Buy Now for 6% Yields

Top TSX dividend stocks now trade at discounted prices.

Read more »

Tired or stressed businessman sitting on the walkway in panic digital stock market financial background
Dividend Stocks

Which Canadian Stocks to Buy Ahead of a 2023 Recession?

Fortis stock may not be cheap, but it looks like a far better bet than bonds or GICs as rates…

Read more »